Lindsay L Peterson1, Maryam Lustberg2, Sara M Tolaney3, Mikel Ross4, Elahe Salehi3, Steven J Isakoff5
1Division of Medical Oncology, Washington University School of Medicine, St. Louis, MO, USA.
2Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA.
3Dana Farber Cancer Institute, Boston, MA, USA.
4Memorial Sloan Kettering Cancer Center, New York, NY, USA.
5Massachusetts General Hosp Cancer Center, Boston, MA, USA.
Scalp cooling (SC) is an effective and generally well-tolerated method for prevention of chemotherapy-induced alopecia (CIA). Initially studied in early-stage breast cancer, these devices have expanded US Food and Drug Administration (FDA) clearance in a broad range of solid tumors including ovarian, colorectal, and prostate. Introducing SC to eligible patients, including those distraught by concerns of CIA, requires an integrated effort on the part of the physician, nursing, and care manager medical team. This article presents a pragmatic workflow for collaborative efforts from physicians and allied health professionals in the USA to deliver supportive SC to reduce CIA in patients undergoing treatment regimens known to impact hair follicles. It further highlights the efforts required to identify appropriate patients, educate, and set expectations of patients. The supervisory role of the physician during the procedure, the nursing role in monitoring and documentation, and the post-procedure decision-making by the physician are also addressed. Lastly, it suggests that integrated physician and nursing efforts necessary for scalp cooling are similar to other care used in oncology.
Adverse effects; Alopecia; Chemotherapy; Cold caps; Quality of life; Scalp cooling; Solid tumors; Supportive care.
